Comparison of Sorafenib response evaluation with RECIST, mRECIST and RECICL for hepatocellular carcinoma

DOI Web Site Web Site 5 Citations 7 References
  • Murakami Eisuke
    Medicine and Molecular Science, Division of Frontier Medical Science, Hiroshima University Graduate School of Biomedical Science
  • Aikata Hiroshi
    Medicine and Molecular Science, Division of Frontier Medical Science, Hiroshima University Graduate School of Biomedical Science
  • Miyaki Daisuke
    Medicine and Molecular Science, Division of Frontier Medical Science, Hiroshima University Graduate School of Biomedical Science
  • Nagaoki Yuko
    Medicine and Molecular Science, Division of Frontier Medical Science, Hiroshima University Graduate School of Biomedical Science
  • Hashimoto Yoshimasa
    Medicine and Molecular Science, Division of Frontier Medical Science, Hiroshima University Graduate School of Biomedical Science
  • Katamura Yoshio
    Medicine and Molecular Science, Division of Frontier Medical Science, Hiroshima University Graduate School of Biomedical Science
  • Kawaoka Tomokazu
    Medicine and Molecular Science, Division of Frontier Medical Science, Hiroshima University Graduate School of Biomedical Science
  • Takaki Shintaro
    Medicine and Molecular Science, Division of Frontier Medical Science, Hiroshima University Graduate School of Biomedical Science
  • Hiramatsu Akira
    Medicine and Molecular Science, Division of Frontier Medical Science, Hiroshima University Graduate School of Biomedical Science
  • Waki Koji
    Medicine and Molecular Science, Division of Frontier Medical Science, Hiroshima University Graduate School of Biomedical Science
  • Takahashi Shoichi
    Medicine and Molecular Science, Division of Frontier Medical Science, Hiroshima University Graduate School of Biomedical Science
  • Chayama Kazuaki
    Medicine and Molecular Science, Division of Frontier Medical Science, Hiroshima University Graduate School of Biomedical Science

Bibliographic Information

Other Title
  • 肝細胞癌のソラフェニブ治療効果判定におけるＲＥＣＩＳＴ，ｍｏｄｉｆｉｅｄ　ＲＥＣＩＳＴ，ＲＥＣＩＣＬ基準の比較
  • カン サイボウガン ノ ソラフェニブ チリョウ コウカ ハンテイ ニ オケル RECIST modified RECIST RECICL キジュン ノ ヒカク

Search this article

Description

RECIST, mRECIST and RECICL are criteria for evaluating the therapeutic response of hepatocellular carcinoma and there are several differences among these criteria. We investigated and compared differences in the response evaluation of sorafenib treatment. As a result, mRECIST and RECIST showed a 59% disease control rate, while RECICL and mRECIST showed an 11% response rate. In RECIST and mRECIST, CR/PR/SD groups demonstrated a significantly better prognosis (P=0.02) than PD. The SD group prognosis was significantly better (P=0.045) than that of the PD group in mRECIST. Multivariate analysis of factors contributing to survival yielded the following values: disease control of mRECIST or RECIST (P=0.005), Vp (P=0.008) and pre-treatment DCP (P=0.047). Concerning Sorafenib therapy, mRECIST tend to stratify the prognosis and was considered the most useful criteria at this time.<br>

Journal

  • Kanzo

    Kanzo 52 (5), 322-324, 2011

    The Japan Society of Hepatology

Citations (5)*help

See more

References(7)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top